Noam Y. Kirson

2.6k total citations · 2 hit papers
87 papers, 1.8k citations indexed

About

Noam Y. Kirson is a scholar working on Economics and Econometrics, Epidemiology and Psychiatry and Mental health. According to data from OpenAlex, Noam Y. Kirson has authored 87 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Economics and Econometrics, 20 papers in Epidemiology and 19 papers in Psychiatry and Mental health. Recurrent topics in Noam Y. Kirson's work include Health Systems, Economic Evaluations, Quality of Life (21 papers), Dementia and Cognitive Impairment Research (18 papers) and Opioid Use Disorder Treatment (15 papers). Noam Y. Kirson is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (21 papers), Dementia and Cognitive Impairment Research (18 papers) and Opioid Use Disorder Treatment (15 papers). Noam Y. Kirson collaborates with scholars based in United States, France and United Kingdom. Noam Y. Kirson's co-authors include Howard G. Birnbaum, Urvi Desai, J. Scott Andrews, Amie Shei, Daniel Ball, Miriam L. Zichlin, Brandy R. Matthews, Rami Ben‐Joseph, Alice Kate G. Cummings and Vijay N. Joish and has published in prestigious journals such as PLoS ONE, Diabetes Care and Nature Reviews Drug Discovery.

In The Last Decade

Noam Y. Kirson

81 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials

2019 221 citations Urvi Desai, Noam Y. Kirson et al. profile →
The Economic Burden of Schizophrenia in the United States

2022 110 citations Noam Y. Kirson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Noam Y. Kirson United States	25	514	420	353	236	224	87	1.8k
Kenneth K. C. Man Hong Kong	30	552 1.1×	412 1.0×	255 0.7×	207 0.9×	116 0.5×	126	2.5k
Fatemeh Yazdi Canada	23	288 0.6×	438 1.0×	220 0.6×	119 0.5×	169 0.8×	58	2.0k
Francesca Cunningham United States	28	625 1.2×	289 0.7×	337 1.0×	397 1.7×	154 0.7×	109	2.9k
Ariel Berger United States	25	501 1.0×	267 0.6×	208 0.6×	163 0.7×	413 1.8×	82	2.1k
Judy A. Staffa United States	19	237 0.5×	629 1.5×	228 0.6×	204 0.9×	104 0.5×	37	2.3k
Hadas D. Fischer Canada	30	687 1.3×	206 0.5×	464 1.3×	266 1.1×	180 0.8×	83	2.9k
François Montastruc France	29	431 0.8×	211 0.5×	153 0.4×	147 0.6×	109 0.5×	145	2.3k
Michael F. Mayo‐Smith United States	17	186 0.4×	652 1.6×	392 1.1×	332 1.4×	289 1.3×	33	2.6k
Matthew S. Shotwell United States	27	189 0.4×	328 0.8×	274 0.8×	110 0.5×	265 1.2×	154	2.8k
Stephanie L. Harrison United Kingdom	27	754 1.5×	183 0.4×	367 1.0×	203 0.9×	184 0.8×	96	2.5k

Countries citing papers authored by Noam Y. Kirson

Since Specialization

Citations

This map shows the geographic impact of Noam Y. Kirson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noam Y. Kirson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noam Y. Kirson more than expected).

Fields of papers citing papers by Noam Y. Kirson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noam Y. Kirson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noam Y. Kirson. The network helps show where Noam Y. Kirson may publish in the future.

Co-authorship network of co-authors of Noam Y. Kirson

This figure shows the co-authorship network connecting the top 25 collaborators of Noam Y. Kirson. A scholar is included among the top collaborators of Noam Y. Kirson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noam Y. Kirson. Noam Y. Kirson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Done, Nicolae, Alan Brnabic, Ilya Lipkovich, et al.. (2026). Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study. Journal of Endocrinological Investigation. 49(2). 413–423.

Hasbun, Rodrigo, et al.. (2025). Modeling the economic impact of different testing strategies for meningitis/encephalitis in adult patients from a US hospital perspective. Diagnostic Microbiology and Infectious Disease. 113(1). 116869–116869.

Diaz‐Decaro, John, et al.. (2025). Epidemiology and Economic Burden of Diagnosed Congenital Cytomegalovirus Infection in the First 2 Years of Life among Commercially Insured and Medicaid-Insured Individuals in the United States. Clinical Therapeutics. 47(6). 426–435.

Buck, Philip O., Ekkehard Beck, Noam Y. Kirson, et al.. (2024). New Vaccine Platforms—Novel Dimensions of Economic and Societal Value and Their Measurement. Vaccines. 12(3). 234–234. 2 indexed citations

Clemens, Kristin K., Amanda Teeple, Benoît Rive, et al.. (2024). Cost Efficiency of Esketamine Nasal Spray Versus Quetiapine for Treatment Resistant Depression. CNS Spectrums. 29(5). 526–527. 1 indexed citations

Chandler, Julie, Urvi Desai, Nicolae Done, et al.. (2024). Impact of Differential Rates of Disease Progression in Amyloid-Positive Early Alzheimer's Disease: Findings from a Longitudinal Cohort Analysis. The Journal of Prevention of Alzheimer s Disease. 11(2). 320–328. 3 indexed citations

Desai, Urvi, et al.. (2024). Understanding the impact of slowing disease progression for individuals with biomarker-confirmed early symptomatic Alzheimer’s disease. Current Medical Research and Opinion. 40(10). 1719–1725. 1 indexed citations

Preston, Mark A., et al.. (2024). Implications of Delayed Testosterone Recovery in Patients with Prostate Cancer. European Urology Open Science. 60. 32–35. 3 indexed citations

Miloh, Tamir, et al.. (2023). Costs of pediatric liver transplantation among commercially insured and Medicaid-insured patients with cholestasis in the US. Liver Transplantation. 29(7). 735–744. 5 indexed citations

10.

LaMori, Joyce, et al.. (2022). Assessing barriers to access and equity for COVID-19 vaccination in the US. BMC Public Health. 22(1). 2263–2263. 23 indexed citations

11.

Thompson‐Leduc, Philippe, et al.. (2022). Assessment of the Impact of a Meningitis/Encephalitis Panel on Hospital Length of Stay: A Systematic Review and Meta-Analysis. Antibiotics. 11(8). 1028–1028. 19 indexed citations

12.

Dell’Agnello, Grazia, Urvi Desai, Noam Y. Kirson, et al.. (2018). Reliability of coded data to identify earliest indications of cognitive decline, cognitive evaluation and Alzheimer’s disease diagnosis: a pilot study in England. BMJ Open. 8(3). e019684–e019684. 6 indexed citations

13.

Cutler, David, et al.. (2017). Insurance switching and mismatch between the costs and benefits of new technologies.. PubMed. 23(12). 750–757. 9 indexed citations

14.

Scarpati, Lauren M., et al.. (2017). Drivers of excess costs of opioid abuse among a commercially insured population.. PubMed. 23(5). 276–282. 7 indexed citations

15.

Hunter, Craig, Noam Y. Kirson, Urvi Desai, et al.. (2015). Medical costs of Alzheimer's disease misdiagnosis among US Medicare beneficiaries. Alzheimer s & Dementia. 11(8). 887–895. 48 indexed citations

16.

Shei, Amie, et al.. (2015). Sources of prescription opioids among diagnosed opioid abusers. Current Medical Research and Opinion. 31(4). 779–784. 65 indexed citations

17.

Shei, Amie, et al.. (2015). Characteristics of High-Cost Patients Diagnosed with Opioid Abuse. Journal of Managed Care & Specialty Pharmacy. 21(10). 902–912. 21 indexed citations

18.

Kirson, Noam Y., Amie Shei, Howard G. Birnbaum, Rami Ben‐Joseph, & Edward Michna. (2014). Medical resource use and costs among pain patients with potential opioid-tolerability issues. Journal of Opioid Management. 10(5). 305–310. 1 indexed citations

19.

Michna, Edward, Noam Y. Kirson, Amie Shei, Howard G. Birnbaum, & Rami Ben‐Joseph. (2014). Use of prescription opioids with abuse-deterrent technology to address opioid abuse. Current Medical Research and Opinion. 30(8). 1589–1598. 14 indexed citations

20.

Kirson, Noam Y., et al.. (2010). Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Direct Cost of Illness in the US Privately Insured Population. CHEST Journal. 138(4). 375A–375A. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact